HLD-0915, a RIPTACT therapeutic, targets mCRPC by linking the androgen receptor with an effector protein, disrupting cancer cell functions. The phase 1/2 trial will evaluate HLD-0915's safety, ...
NEW HAVEN, Conn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of therapies called RIPTAC™ Therapeutics, today announced that ...
BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics today announced that new clinical data on HLD-0915, the company’s first-in-class oral RIPTAC™ therapeutic, will be presented at the plenary ...
BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics announced today new data from a Phase 1/2 study evaluating HLD-0915, a first-in-class, oral RIPTAC™ therapeutic, in patients with ...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of cancer therapies called RIPTAC™ (Regulated Induced Proximity TArgeting ...
In preclinical prostate cancer models, HLD-0915 treatment resulted in tumor shrinkage and declines in prostate-specific antigen. The Food and Drug Administration (FDA) has granted Fast Track ...
HLD-0915 has received FDA fast track designation for mCRPC, expediting its development and review process to address unmet medical needs. Halda Therapeutics is conducting a phase 1/2 clinical trial to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results